Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The ...

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

Its products include multi-function single phase meter, polycarbonate meter boxes, polycarbonate distribution boxes, emergency lights, three phase smart energy LT CT Meter, light-emitting diodes ...